SUBSTITUTED FURANS AND THEIR USE

• US 20110054017A1
• Filed: 01/29/2009
• Published: 03/03/2011
• Est. Priority Date: 02/04/2008
• Status: Abandoned Application

• Current Assignee: Bayer Intellectual Property GmbH (Bayer AG)
• Original Assignee: Bayer Intellectual Property GmbH (Bayer AG)
• Inventors: Lampe, Thomas, Schuhmacher, Joachim, Stoll, Friederike, Kast, Raimund
• Application Number:
  US12/866,132
• Publication Number:
  US 20110054017A1
• Time in Patent Office: Days
• US Class Current: 514/471
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/08 Vasodilators for multiple indications
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07D 307/42 Singly bound oxygen atoms
• CPC Class Codes: C07D 307/52 Radicals substituted by nitrogen atoms not forming part of a nitro radical
• CPC Class Codes: C07D 307/54 Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

The present application relates to novel substituted furan derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular diseases.

Claims

1. A compound of the formula (I)

2. The compound of formula (I) as claimed in claim 1 in which

A represents —

CH₂—

or —

C(═

O)—

,

E represents O or NR⁴,

where

R⁴ represents hydrogen or (C₁-C₄)-alkyl,

M represents a group of the formula

3. The compound of formula (I) as claimed in claim 1 in which

A represents —

CH₂—

or —

C(═

O)—

,

E represents O or NR⁴,

where

R⁴ represents hydrogen,

M represents a group of the formula

4. A process for preparing compounds of formula (I) as defined in claim 1 in which Z represents —

COOH, wherein either

[A] (1) a compound of the formula (II-A),

8. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 and an inert non-toxic pharmaceutically suitable auxiliary.

9. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 and an additional active compound.

11. A method for the treatment and/or prophylaxis of angina pectoris, pulmonary hypertension, thromboembolic disorders and peripheral occlusive diseases comprising administering to a human or animal in need thereof an effective amount of at least one compound of the formula (I) as defined in claim 1.

12. A process for preparing compounds of formula (I) as defined in claim 2 in which Z represents —

COOH, wherein either

[A] (1) a compound of the formula (II-A),

13. A process for preparing compounds of formula (I) as defined in claim 3 in which Z represents —

COOH, wherein either

[A] (1) a compound of the formula (II-A),

14. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 2 and an inert non-toxic pharmaceutically suitable auxiliary.

15. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 3 and an inert non-toxic pharmaceutically suitable auxiliary.

16. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 2 and an additional active compound.

17. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 3 and an additional active compound.

18. A method for the treatment and/or prophylaxis of angina pectoris, pulmonary hypertension, thromboembolic disorders and peripheral occlusive diseases comprising administering to a human or animal in need thereof an effective amount of at least one compound of formula (I) as defined in claim 2.

19. A method for the treatment and/or prophylaxis of angina pectoris, pulmonary hypertension, thromboembolic disorders and peripheral occlusive diseases comprising administering to a human or animal in need thereof an effective amount of at least one compound of formula (I) as defined in claim 3.

20. A method for the treatment and/or prophylaxis of angina pectoris, pulmonary hypertension, thromboembolic disorders and peripheral occlusive diseases comprising administering to a human or animal in need thereof an effective amount of the pharmaceutical composition of claim 9.

21. A method for the treatment and/or prophylaxis of angina pectoris, pulmonary hypertension, thromboembolic disorders and peripheral occlusive diseases comprising administering to a human or animal in need thereof an effective amount of the pharmaceutical composition of claim 16.

22. A method for the treatment and/or prophylaxis of angina pectoris, pulmonary hypertension, thromboembolic disorders and peripheral occlusive diseases comprising administering to a human or animal in need thereof an effective amount of the pharmaceutical composition of claim 17.

5. (canceled)

6. (canceled)

7. (canceled)

10. (canceled)